Cerezyme rival available in trials
To offset drug deficit, FDA permits 2d plan for Gaucher patients
For the second time in two weeks, federal regulators have moved to counter the ongoing supply shortage of Cerezyme, Genzyme Corp.’s treatment for Gaucher disease, by letting doctors prescribe a rival drug before it has won approval for commercial use. (Full article: 758 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
